MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer

PURPOSE: The objective of this study was to investigate the effects of inhibiting the MET receptor with capmatinib, a potent and clinically relevant ATP-competitive tyrosine kinase inhibitor, in combination with radiation in MET exon 14-mutated and MET-amplified non-small cell lung (NSCLC) cancer mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramesh, Shrey, Cifci, Ahmet, Javeri, Saahil, Minne, Rachel, Longhurst, Colin A., Nickel, Kwangok P., Kimple, Randall J., Baschnagel, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634863/
https://www.ncbi.nlm.nih.gov/pubmed/37961176
http://dx.doi.org/10.1101/2023.10.26.564232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634863/
https://www.ncbi.nlm.nih.gov/pubmed/37961176
http://dx.doi.org/10.1101/2023.10.26.564232

Ejemplares similares